A Randomised, Double-blind, Placebo- and Active Comparator-controlled, Five Parallel Groups Study to Investigate the Efficacy and Safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) Administered Orally Once During an Acute Migraine Attack of Moderate or Severe Intensity
Latest Information Update: 06 Oct 2021
At a glance
- Drugs BI 44370 (Primary) ; Eletriptan
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 23 Oct 2012 Planned number of patients changed from 410 to 460 as reported by European Clinical Trials Database record.
- 03 Jul 2012 Official title amended as reported by European Clinical Trials Database record.
- 01 Jul 2009 Actual patient number (416) added as reported by ClinicalTrials.gov.